1Joy T,Hegele RA.The end of the road for CETP inhibitors after torcetrapib[J].Curr Opin Cardiol,2009,24(4):364.
2Curtiss LK,Volenta DT,Hime NJ,et al.What is so special about apolipoprotein AI in reverse cholesterol transport[J].Arterioscler Thromb Vasc Biol,2006,26(1):12.
3Kontush A,Chapman MJ.Functionally defective high-density lipoprotein:a new therapeutic target at the crossroads of dyslipidemia,inflammation,and atherosclerosis[J].Phamacol Rev,2006,58(3):342.
4Kapur NK,Ashen D,Blumenthal RS.High density lipoprotein cholesterol:anevolving target of therapy in the management of cardiovascular disease[J].Vasc Health Risk Manag,2008,4(1):39.
5Gauthier A,Lau P,Zha X,et al.Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver[J].Arterioscler Thromb Vasc Biol,2005,25(10):2177.
6Potter LK,Sprecher DL,Walker MC,et al.Mechanism of inhibition defines CETP activity:a mathematical model for CETP in vitro[J].J Lipid Res,2009,11.
7Nissen SE,Tardif JC,Nicholls SJ,et al.Effect of torcetrapib on the progression of coronary atherosclerosis[J].N Engl J Med,2007,356(13):1304.
8Barter PJ,Caulfield M,Eriksson M,et al.Effects of torcetrapib in patients at high risk for coronary events[J].N Engl J Med,2007,357(21):2109.
10Bloomfield D,Carlson GL,Sapre A,et al.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients[J].Am Heart J,2009,157(2):352.
